A controlled trial of natalizumab for relapsing multiple sclerosis.

@article{Miller2003ACT,
  title={A controlled trial of natalizumab for relapsing multiple sclerosis.},
  author={David H. Miller and Omar A. Khan and William A. Sheremata and Lance D. Blumhardt and George P. Rice and Michele A Libonati and A. J. Willmer-Hulme and Catherine M. Dalton and Katherine A. Miszkiel and P. W. O'Connor},
  journal={The New England journal of medicine},
  year={2003},
  volume={348 1},
  pages={
          15-23
        }
}
BACKGROUND In patients with multiple sclerosis, inflammatory brain lesions appear to arise from autoimmune responses involving activated lymphocytes and monocytes. The glycoprotein alpha4 integrin is expressed on the surface of these cells and plays a critical part in their adhesion to the vascular endothelium and migration into the parenchyma. Natalizumab is an alpha4 integrin antagonist that reduced the development of brain lesions in experimental models and in a preliminary study of patients… 

Figures and Tables from this paper

The effect of natalizumab on disability score and relapse rate of multiple sclerosis patients: a prospective cohort study
TLDR
Natalizumab is effective in improvement of disability and reduction of relapse rate in MS patients and number of relapses was significantly lower in natalIZumab treated patients compared with control group.
Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis
TLDR
There was a lower proportion of subjects with an on-study relapse in natalizumab-treated patients, particularly in those with a more active disease at study entry, and the difference was most apparent in the subgroups of patients with >3 relapses in the two years prior to study entry and >2 new Gd+ lesions at Month 0.
Randomized multicenter trial of natalizumab in acute MS relapses
TLDR
A single dose of IV natalizumab did not hasten clinical recovery after relapse, although a significant decrease in Gd-enhancing lesion volume was observed at 1 and 3 weeks after treatment.
Natalizumab use in pediatric multiple sclerosis.
TLDR
Natalizumab treatment was effective and well tolerated in pediatric patients with RRMS who did not respond to initial immunomodulatory treatments and is a promising second-line therapy for pediatric patientswith RRMS.
Natalizumab in multiple sclerosis: proceed with caution?
  • S. Doggrell
  • Medicine, Psychology
    Expert opinion on pharmacotherapy
  • 2006
TLDR
Large numbers of patients should not be allowed to take natalizumab until its safety has been monitored in the long-term use in a clinical trial environment, the author’s opinion.
Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring
TLDR
Mechanisms of action involved in therapeutic efficacy as well as in PML risk will be discussed, and the interest of a biological monitoring that may be helpful to rapidly adapt treatment is presented.
Role of Natalizumab in Relapsing-Remitting Multiple Sclerosis: A review
TLDR
The literature review suggests that natalizumab reduces the rate of sustained progression of the disease and disability, and was associated with a lower relapse rate in patients with relapsing-remitting multiple sclerosis, however, Progressive multifocal leukoencephalopathy is one of the serious side effects of natalizer.
Efficacy and Side Effects of Natalizumab Therapy in Patients with Multiple Sclerosis
TLDR
Data is reviewed on the presumed mechanism of Nat action, clinical and paraclinical efficacy parameters, and adverse drug reactions with a special focus on PML.
The use of natalizumab for multiple sclerosis
TLDR
Natalizumab’s high efficacy and favorable tolerability profile have led to a broad use by MS physicians, as both first- and second-line treatments, and pragmatic considerations regarding its use in clinical practice are finished.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 27 REFERENCES
Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis
TLDR
Evidence is provided supporting the emerging view that treatment in multiple sclerosis must be given early in the course, before the consequences of inflammation are irretrievably established, and the formulation that inflammation and demyelination are responsible for relapses of multiple sclerosis is supported.
Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis
TLDR
Interferon beta‐ la had a significant beneficial impact in relapsing multiple sclerosis patients by reducing the accumulation of permanent physical disability, exacerbation frequency, and disease activity measured by gadolinium‐enhanced lesions on brain magnetic resonance images.
Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis
TLDR
It is demonstrated that copolymer 1 treatment can significantly and beneficially alter the course of relapsing-remitting multiple sclerosis in a well-tolerated fashion.
The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group.
TLDR
Short-term treatment with monoclonal antibody against alpha4 integrin results in a significant reduction in the number of new active lesions on MRI, and further studies are required to determine the longer term effect of this treatment on MRI and clinical outcomes.
Serial gadolinium‐enhanced magnetic resonance imaging scans in patients with early, relapsing‐remitting multiple sclerosis: Implications for clinical trials and natural history
TLDR
The opening of the blood‐brain barrier as reflected by gadolinium enhancement on magnetic resonance imaging may represent ongoing disease activity in patients with mild, relapsing‐remitting multiple sclerosis who are clinically stable.
Major differences in the dynamics of primary and secondary progressive multiple sclerosis
TLDR
Findings may indicate a difference in the dynamics of disease activity between the two forms of progressive MS, particularly in relation to the inflammatory component of the lesions, and have important implications for the selection of patients and the monitoring of diseaseactivity in therapeutic trials.
Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.
TLDR
In vitro adhesion assay on tissue sections found that lymphocytes and monocytes bound selectively to inflamed EAE brain vessels, and therapies designed to interfere with alpha 4 beta 1 integrin may be useful in treating inflammatory diseases of the central nervous system, such as multiple sclerosis.
European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis
TLDR
Glatiramer acetate significantly reduced MRI‐measured disease activity and burden in patients with relapsing remitting multiple sclerosis and increased over time.
...
1
2
3
...